Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients

ONCOLOGY

Volumn 24, Issue 3, 2010, Pages

  Kurniali, Peter C ^a   Luo, Lu Guang ^a   Weitberg, Alan B ^b,c,d  

^a Roger Williams Medical Center   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN;

ADVANCED CANCER; BIOTRANSFORMATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; COLORECTAL CANCER; DNA REPLICATION; DRUG EFFICACY; HUMAN; INFUSION SYSTEM; NEUROTOXICITY; NOTE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RADIOFREQUENCY ABLATION;

EID: 77950808829     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (35)

1. Jemal A, Siegel R, Ward EM, et al.: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009.
2. US Cancer Statistics Working Group: United States cancer statistics: 19992004 incidence and mortality Web-based report. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2007.
3. Ries LAG, Melbert D, Krapcho M, et al. (eds): SEER cancer statistics review, 19752005. National Cancer Institute. Bethesda, Md. Available at www.seer.cancer.gov/csr/1975-2005/. Accessed February 11, 2010.
4. OConnell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420, 2004.
5. American Joint Committee on Cancer: Colon and rectum, in AJCC Cancer Staging Manual, 5th ed, pp 83-90. Philadelphia, Lippincott-Raven, 1997.
6. Van Cutsem E, Dicato M, Haustermans K, et al.: The diagnosis and management of rectal cancer: Expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 19(suppl 6):vi1-vi8, 2008.
7. Melville A, Sheldon TA, Gray R, et al.: Management of colorectal cancer. Qual Health Care 7:103-108, 1998.
8. Sobrero A, Guglielmi A, Grossi F, et al.: Mechanism of action of fluoropyrimidines: Relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 27(suppl 10):72-77, 2000.
9. Zhang ZG, Harstrick A, Rustum YM: Modulation of fluoropyrimidines: Role of dose and schedule of leucovorin administration. Semin Oncol 19(suppl 3):10-15, 1992.
10. Wolmark N, Fisher B, Rockette H, et al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 80:30-36, 1988. (Pubitemid 18076566)
11. Wolmark N, Wieand HS, Hyams DM, et al.: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92:361-362, 2000.
12. Raymond E, Faivre S, Woynarowski JM, et al.: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998.
13. Rixe O, Ortuzar W, Alvarez M, et al.: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institutes Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996.
14. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
15. Fischel JL, Etienne MC, Formento P, et al.: Search for the optimal schedule for the oxaliplatin/5-fluorourail association modulated or not by folinic acid: Precelinical data. Clin Cancer Res 4:1021-1029, 1998.
16. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005.
17. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000.
18. Andre T, Boni C, Mounedji-Boudiaf, et al.: Oxalipatin, fluorouracil, and leucovorin as adjuvant treatment for colorectal cancer. N Engl J Med 350:2343-2351, 2004.
19. de Gramont A, Banzi M, Navarro M, et al.: Oxaliplatin/5-FU/LV in adjuvant colon cancer: Result of the international randomized MOSAIC trial (abstract 1015). Proc Am Soc Clin Oncol 22:253, 2003.
20. Meyerhardt J, Mayer R: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005.
21. Goldberg RM, Sagent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated colorectal cancer. J Clin Oncol 22:23-30, 2004.
22. Sanofi-aventis: Eloxatin: Assessing neuropathy. Available at http://www.eloxatin.com/. Accessed February 11, 2010.
23. Saif MW, Reardon J: Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2:249-258, 2005.
24. Gamelin L, Capitain O, Morel A, et al.: Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clin Cancer Res 13:6359-6368, 2007.
25. Wilson RH, Lehky T, Thomas RR, et al.: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774, 2002.
26. Graham J, Mushin M, Kirkpatrick P: Oxaliplatin. Nat Rev Drug Discov 3:11-12, 2004.
27. Grolleau F, Gamelin L, Boisdron-Celle M: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channel. J Neurophysiol 85:2293-2297, 2001.
28. Gamelin L, Boisdron-Celle M, Morel A: Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188-1189, 2008.
29. Horn R: The dual role of calcium: Pore blocker and modulator of gating. Proc Natl Acad Sci 96:3331-3332, 1999.
30. Gamelin L, Boisdron-Celle M, Delva R: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusion: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for adavanced colorectal cancer. Clin Cancer Res 10:4055-4061, 2004.
31. Hochster H, Grothey A, Childs B: Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity (letter). J Clin Oncol 25:4028a-4029a, 2007.
32. National Institutes of Health: CONCEPT: Comparison of oxaliplatin vs conventional methods with calcium/magnesium in first-line metastatic colorectal cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00129870. Accessed February 11, 2010.
33. Hochster HS, Grothey A, Shpilsky A, et al.: Effect of intravenous (IV) calcium and mangnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial (abstract 280). ASCO 2008 Gastrointestinal Cancers Symposium; Orlando, Fla; January 25-27, 2008.
34. Nikcevich DA, Grothey A, Sloan JA, et al.: Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Result of the phase III placebo-controlled, double-blind NCCTG trial N04C7 (abstract 4009). J Clin Oncol 26(15S):180s, 2008.
35. Grothey A: Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(suppl 1):S38-S46, 2005.